A blood test for glioblastoma may be on the horizons, as researchers identify novel biomarkers that could be used for diagnosis.
A Phase I clinical trial presents veledimex – a drug-inducible gene therapy approach – as a promising treatment technique for glioblastoma.
In order to slow the accumulation of white matter lesions, researchers reveal that it is more effective to intensively control a person’s blood pressure compared to the standard care of high blood pressure.
Chronic active lesions (‘smoldering’ spots) may be a hallmark for progressive forms of multiple sclerosis, a recently published study suggests.
A wireless drug-delivery system to the brain has been developed in mice, which includes a replaceable drug cartridge and can be controlled by using a smartphone.
Positive results for Emgality® (galcanezumab) have been reported from the CONQUER study in patients who failed previous migraine preventive treatments.
A blood test to diagnose individuals at risk of developing Alzheimer’s disease before symptoms arise may be closer to reality, as researchers report a 94% accuracy in recent findings.
Researchers have identified that α-synuclein plays a role in DNA repair in neurons and that disruption of this function could lead to widespread death of neurons.
This week in industry includes trials on ponesimod for relapsing multiple sclerosis, the Accordion Pill® for Parkinson’s and cannabidiol oral solution for seizures.
MRI scans of individuals living with multiple sclerosis could predict how the disease will progress in the following years. This information could potentially be useful when considering treatment options.